## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

## Listing of Claims:

- 1. (currently amended) A condensation aerosol for delivery of a drug selected from the group consising of zaleplon, zolpidem and zopiclone, wherein the condensation aerosol is formed by heating a thin layer containing the drug, on a solid support, to produce a vapor of the drug, and condensing the vapor to form a condensation aerosol characterized by less than 10% drug degradation products by weight, and an MMAD of less than 5 microns.
- 2. (previously presented) The condensation aerosol according to Claim 1, wherein the condensation aerosol is formed at a rate greater than  $10^9$  particles per second.
- 3. (previously presented) The condensation aerosol according to Claim 2, wherein the condensation aerosol is formed at a rate greater than  $10^{10}$  particles per second.

## 4.-9. (cancelled)

- 10. (previously presented) A method of producing a drug selected from the group consising of zaleplon, zolpidem and zopiclone in an aerosol form comprising:
- a. heating a thin layer containing the drug, on a solid support, to produce a vapor of the drug, and
- b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 10% drug degradation products, and an MMAD of less than 5 microns.
- 11. (previously presented) The method according to Claim 10, wherein the condensation aerosol is formed at a rate greater than 10<sup>9</sup> particles per second.
  - 12. (previously presented) The method according to Claim 11, wherein the

condensation aerosol is formed at a rate greater than 10<sup>10</sup> particles per second

## 13.-18 (cancelled)

- 19. (previously presented) The condensation aerosol according to Claim 1, wherein the condensation aerosol is characterized by an MMAD of 0.2 to 5 microns.
- 20. (previously presented) The condensation aerosol according to Claim 1, wherein the condensation aerosol is characterized by an MMAD of less than 3 microns.
- 21. (currently amended) The condensation aerosol according to Claim 19, wherein the condensation aerosol is characterized by an MMAD of 0.2 and to 3 microns.
- 22. (currently amended) The condensation aerosol according to Claim 1, wherein the condensation aerosol is characterized by less than 5% drug ester degradation products by weight.
- 23. (currently amended) The condensation aerosol according to Claim 22, wherein the condensation aerosol is characterized by less than 2.5% drug ester degradation products by weight.
- 24. (previously presented) The condensation aerosol according to Claim 1, wherein the solid support is a metal foil.
- 25. (previously presented) The condensation aerosol according to claim 1, wherein the thin layer has a thickness between 1.5 and 4.4 microns.
- 26. (previously presented) The condensation aerosol according to Claim 1, wherein the drug is zaleplon.
- 27. (previously presented) The condensation aerosol according to Claim 1, wherein the drug is zolpidem.

- 28. (previously presented) The condensation aerosol according to Claim 1, wherein the drug is zopiclone.
- 29. (previously presented) The method according to Claim 10, wherein the condensation aerosol is characterized by an MMAD of 0.2 to 5 microns.
- 30. (previously presented) The method according to Claim 10, wherein the condensation aerosol is characterized by an MMAD of less than 3 microns.
- 31. (previously presented) The method according to Claim 29, wherein the condensation aerosol is characterized by an MMAD of 0.2 to 3 microns.
- 32. (currently amended) The method according to Claim 10, wherein the condensation aerosol is characterized by less than 5% drug ester degradation products by weight.
- 33. (currently amended) The method according to Claim 32, wherein the condensation aerosol is characterized by less than 2.5% drug ester degradation products by weight.
- 34. (previously presented) The method according to Claim 10, wherein the solid support is a metal foil.
- 35. (previously presented) The method according to claim 1, wherein the thin layer has a thickness between 1.5 and 4.4 microns.
- 36. (previously presented) The method according to Claim 10, wherein the drug is zaleplon.
- 37. (previously presented) The method according to Claim 10, wherein the drug is zolpidem.

- 38. (previously presented) The method according to Claim 10, wherein the drug is zopiclone.
- 39. (previously presented) A condensation aerosol for delivery of zaleplon, wherein the condensation aerosol is formed by heating a thin layer containing zaleplon, on a solid support, to produce a vapor of zaleplon, and condensing the vapor to form a condensation aerosol characterized by less than 5% zaleplon degradation products by weight, and an MMAD of 0.2 to 3 microns.
- 40. (previously presented) A condensation aerosol for delivery of zolpidem, wherein the condensation aerosol is formed by heating a thin layer containing zolpidem, on a solid support, to produce a vapor of zolpidem, and condensing the vapor to form a condensation aerosol characterized by less than 5% zolpidem degradation products by weight, and an MMAD of 0.2 to 3 microns.
- 41. (previously presented) A condensation aerosol for delivery of zopiclone, wherein the condensation aerosol is formed by heating a thin layer containing zopiclone, on a solid support, to produce a vapor of zopiclone, and condensing the vapor to form a condensation aerosol characterized by less than 5% zopiclone degradation products by weight, and an MMAD of 0.2 to 3 microns.
- 42. (previously presented) A method of producing zaleplon in an aerosol form comprising:
- a. heating a thin layer containing zaleplon, on a solid support, to produce a vapor of zaleplon, and
- b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% zaleplon degradation products by weight, and an MMAD of 0.2 to 3 microns.

- 43. (previously presented) A method of producing zolpidem in an aerosol form comprising:
- a. heating a thin layer containing zolpidem, on a solid support, to produce a vapor of zolpidem, and
- b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% zolpidem degradation products by weight, and an MMAD of 0.2 to 3 microns.
- 44. (previously presented) A method of producing zopiclone in an aerosol form comprising:
- a. heating a thin layer containing zopiclone, on a solid support, to produce a vapor of zopiclone, and
- b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% zopiclone degradation products by weight, and an MMAD of 0.2 to 3 microns.